(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of 16.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Kymera Therapeutics's revenue in 2025 is $58,885,000.On average, 11 Wall Street analysts forecast KYMR's revenue for 2025 to be $5,193,611,146, with the lowest KYMR revenue forecast at $1,439,142,453, and the highest KYMR revenue forecast at $14,651,902,800. On average, 10 Wall Street analysts forecast KYMR's revenue for 2026 to be $4,462,253,278, with the lowest KYMR revenue forecast at $1,302,391,360, and the highest KYMR revenue forecast at $9,767,935,200.
In 2027, KYMR is forecast to generate $6,700,412,830 in revenue, with the lowest revenue forecast at $2,604,782,720 and the highest revenue forecast at $12,795,995,112.